Shuren Touts Pre-Market Benefits Of Planned National Post-Market Strategy
This article was originally published in The Gray Sheet
CDRH is drafting a national comprehensive post-market strategy, due out this spring. While a principle goal is catching safety problems earlier, Jeffrey Shuren hopes the plan will ultimately make data collection less burdensome for industry, both in the pre-market and post-market stages.
You may also be interested in...
AdvaMed's new chief Scott Whitaker says industry doesn't want to sign onto a new "national evaluation system" for devices championed by FDA until it is convinced that the initiative will enhance, rather than hinder, premarket product development.
FDA plans the imminent release of a white paper outlining a new national medical device post-market surveillance strategy in the lead up to public meetings Sept.10-13. More regulatory news below.
The long-anticipated proposal maps out a unique device identifier system that FDA says will be crucial to the future of post-market safety surveillance, recall management and safety alerts. The effort also will help reduce medical errors and bring an array of other benefits, stakeholders say.